FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384282998> ?p ?o ?g. }

• W4384282998 endingPage "e0288598" @default.
• W4384282998 startingPage "e0288598" @default.
• W4384282998 abstract "Maraviroc may reduce hepatic inflammation in people with HIV and non-alcoholic fatty liver disease (HIV-NAFLD) through CCR5-receptor antagonism, which warrants further exploration.We performed an open-label 96-week randomised-controlled feasibility trial of maraviroc plus optimised background therapy (OBT) versus OBT alone, in a 1:1 ratio, for people with virologically-suppressed HIV-1 and NAFLD without cirrhosis. Dosing followed recommendations for HIV therapy in the Summary of Product Characteristics for maraviroc. The primary outcomes were safety, recruitment and retention rates, adherence and data completeness. Secondary outcomes included the change in Fibroscan-assessed liver stiffness measurements (LSM), controlled attenuation parameter (CAP) and Enhanced Liver Fibrosis (ELF) scores.Fifty-three participants (53/60, 88% of target) were recruited; 23 received maraviroc plus OBT; 89% were male; 19% had type 2 diabetes mellitus. The median baseline LSM, CAP & ELF scores were 6.2 (IQR 4.6-7.8) kPa, 325 (IQR 279-351) dB/m and 9.1 (IQR 8.6-9.6) respectively. Primary outcomes: all individuals eligible after screening were randomised; there was 92% (SD 6.6%) adherence to maraviroc [target >90%]; 83% (95%CI 70%-92%) participant retention [target >65%]; 5.5% of data were missing [target <20%]. There were noo Serious Adverse Reactions; mild-moderate intensity Adverse Reactions were reported by five participants (5/23, 22% (95%CI 5%-49%)) [target <10%]. All Adverse Reactions resolved. Secondary outcomes: no important differences were seen by treatment group for the change from baseline in LSM, CAP or ELF scores.This feasibility study provides preliminary evidence of maraviroc safety amongst people with HIV-NAFLD, and acceptable recruitment, retention, and adherence rates. These data support a definitive randomised-controlled trial assessing maraviroc impact on hepatic steatosis and fibrosis.Clinical trial registry: ISCRTN, registration number 31461655." @default.
• W4384282998 created "2023-07-15" @default.
• W4384282998 creator A5012564817 @default.
• W4384282998 creator A5013078758 @default.
• W4384282998 creator A5014109607 @default.
• W4384282998 creator A5018977216 @default.
• W4384282998 creator A5024771458 @default.
• W4384282998 creator A5025606537 @default.
• W4384282998 creator A5031569455 @default.
• W4384282998 creator A5040934612 @default.
• W4384282998 creator A5042325781 @default.
• W4384282998 creator A5049816215 @default.
• W4384282998 creator A5054082124 @default.
• W4384282998 creator A5070132321 @default.
• W4384282998 creator A5072204769 @default.
• W4384282998 creator A5072739448 @default.
• W4384282998 creator A5073460580 @default.
• W4384282998 creator A5074394540 @default.
• W4384282998 creator A5079948948 @default.
• W4384282998 creator A5092468717 @default.
• W4384282998 creator A5092468718 @default.
• W4384282998 date "2023-07-14" @default.
• W4384282998 modified "2023-09-26" @default.
• W4384282998 title "Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease" @default.
• W4384282998 cites W1606178710 @default.
• W4384282998 cites W1889367418 @default.
• W4384282998 cites W1985722970 @default.
• W4384282998 cites W1990654824 @default.
• W4384282998 cites W2005226910 @default.
• W4384282998 cites W2037377025 @default.
• W4384282998 cites W2055176387 @default.
• W4384282998 cites W2064935802 @default.
• W4384282998 cites W2070553985 @default.
• W4384282998 cites W2086325363 @default.
• W4384282998 cites W2124981797 @default.
• W4384282998 cites W2136547076 @default.
• W4384282998 cites W2137591261 @default.
• W4384282998 cites W2139077271 @default.
• W4384282998 cites W2140740501 @default.
• W4384282998 cites W2160230582 @default.
• W4384282998 cites W2413287636 @default.
• W4384282998 cites W2517544254 @default.
• W4384282998 cites W2534656414 @default.
• W4384282998 cites W2588089969 @default.
• W4384282998 cites W2727332274 @default.
• W4384282998 cites W2734724639 @default.
• W4384282998 cites W2784174507 @default.
• W4384282998 cites W2794770794 @default.
• W4384282998 cites W2946915306 @default.
• W4384282998 cites W2979687596 @default.
• W4384282998 cites W2982216477 @default.
• W4384282998 cites W3000140653 @default.
• W4384282998 cites W3025555823 @default.
• W4384282998 cites W3038544067 @default.
• W4384282998 cites W3083034332 @default.
• W4384282998 cites W3091914276 @default.
• W4384282998 cites W3092825468 @default.
• W4384282998 cites W3143409077 @default.
• W4384282998 cites W3162993738 @default.
• W4384282998 cites W3178977150 @default.
• W4384282998 cites W3198750163 @default.
• W4384282998 cites W4292806894 @default.
• W4384282998 cites W4310847620 @default.
• W4384282998 cites W4316467708 @default.
• W4384282998 doi "https://doi.org/10.1371/journal.pone.0288598" @default.
• W4384282998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37450478" @default.
• W4384282998 hasPublicationYear "2023" @default.
• W4384282998 type Work @default.
• W4384282998 citedByCount "0" @default.
• W4384282998 crossrefType "journal-article" @default.
• W4384282998 hasAuthorship W4384282998A5012564817 @default.
• W4384282998 hasAuthorship W4384282998A5013078758 @default.
• W4384282998 hasAuthorship W4384282998A5014109607 @default.
• W4384282998 hasAuthorship W4384282998A5018977216 @default.
• W4384282998 hasAuthorship W4384282998A5024771458 @default.
• W4384282998 hasAuthorship W4384282998A5025606537 @default.
• W4384282998 hasAuthorship W4384282998A5031569455 @default.
• W4384282998 hasAuthorship W4384282998A5040934612 @default.
• W4384282998 hasAuthorship W4384282998A5042325781 @default.
• W4384282998 hasAuthorship W4384282998A5049816215 @default.
• W4384282998 hasAuthorship W4384282998A5054082124 @default.
• W4384282998 hasAuthorship W4384282998A5070132321 @default.
• W4384282998 hasAuthorship W4384282998A5072204769 @default.
• W4384282998 hasAuthorship W4384282998A5072739448 @default.
• W4384282998 hasAuthorship W4384282998A5073460580 @default.
• W4384282998 hasAuthorship W4384282998A5074394540 @default.
• W4384282998 hasAuthorship W4384282998A5079948948 @default.
• W4384282998 hasAuthorship W4384282998A5092468717 @default.
• W4384282998 hasAuthorship W4384282998A5092468718 @default.
• W4384282998 hasBestOaLocation W43842829981 @default.
• W4384282998 hasConcept C126322002 @default.
• W4384282998 hasConcept C12823836 @default.
• W4384282998 hasConcept C13373296 @default.
• W4384282998 hasConcept C197934379 @default.
• W4384282998 hasConcept C203014093 @default.
• W4384282998 hasConcept C2776914184 @default.
• W4384282998 hasConcept C2777075537 @default.
• W4384282998 hasConcept C2778772119 @default.

• next